Skip to main content
. 2022 Oct 17;14(20):5074. doi: 10.3390/cancers14205074

Figure 3.

Figure 3

Molecular pathways in iCCA. Inhibitors have been developed for well-known signaling pathways including the Raf/MEK/ERK, PI3K-AKT, and JAK/STAT pathway. AKT: protein kinase B; FGFR: fibroblast growth factor; HER2: epidermal growth factor receptor 2; JAK: janus kinase; mTOR: mammalian target of rapamycin; PI3K: phosphoinositide 3-kinase. NTRK: neurotrophic receptor tyrosine kinase.